Bulk Pharmaceutical API Sources for phenprocoumon

Bulk Pharmaceutical API Sources for phenprocoumon

Vendor	Vendor Homepage	Vendor Sku	API Url
NovoSeek		9908
MolPort		MolPort-005-935-554
ABI Chem		AC1L1U3E

Phenprocoumon Bulk API Sourcing Landscape

Last updated: February 19, 2026

This analysis details the global landscape for sourcing bulk active pharmaceutical ingredient (API) phenprocoumon, focusing on key manufacturers, regulatory approvals, and market dynamics relevant to pharmaceutical procurement and R&D.

Who Are the Primary Global Manufacturers of Phenprocoumon API?

The production of phenprocoumon API is concentrated among a limited number of manufacturers, primarily located in Europe and India. These entities supply the global pharmaceutical market with the active ingredient for the anticoagulant drug.

Key identified manufacturers include:

• Alp Pharma S.p.A. (Italy): A significant producer with a history in API manufacturing. Alp Pharma has established processes for the synthesis of phenprocoumon.
• Sanico N.V. (Belgium): This Belgian pharmaceutical company also manufactures phenprocoumon API. Sanico's operations are integrated into the broader European pharmaceutical supply chain.
• Standard Pharmacare Limited (India): A prominent Indian API manufacturer that includes phenprocoumon in its product portfolio. Indian manufacturers play a critical role in the global supply of many APIs due to cost efficiencies and established manufacturing capabilities.

The production volumes and market share of these manufacturers are influenced by factors such as regulatory compliance, production capacity, and cost-competitiveness.

What Are the Key Regulatory Considerations for Phenprocoumon API Sourcing?

Sourcing phenprocoumon API requires adherence to stringent regulatory standards to ensure product quality, safety, and efficacy. Major regulatory bodies, including the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and others, set forth requirements that API manufacturers must meet.

Key regulatory aspects include:

• Good Manufacturing Practices (GMP): Compliance with current GMP is mandatory for API production. This ensures that APIs are consistently produced and controlled according to quality standards appropriate for their intended use.
• Drug Master Files (DMFs): API manufacturers typically submit DMFs to regulatory authorities. A DMF contains confidential, detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of human drugs. Pharmaceutical companies reference these DMFs in their drug product applications.
  • European manufacturers often have Certificates of Suitability to the monographs of the European Pharmacopoeia (CEP). A CEP certifies that a substance complies with the requirements of the relevant monograph of the European Pharmacopoeia.
• Impurity Profiling: Manufacturers must rigorously control and characterize impurities within the phenprocoumon API. This includes identifying, quantifying, and setting acceptance criteria for known and potential impurities.
• Stability Studies: Comprehensive stability data is required to establish the shelf-life of the API under defined storage conditions.
• Pharmacopoeial Compliance: APIs must meet the specifications outlined in relevant pharmacopoeias, such as the European Pharmacopoeia (Ph. Eur.) or the United States Pharmacopeia (USP), where applicable. Phenprocoumon is listed in the Ph. Eur.

Pharmaceutical companies intending to source phenprocoumon API must verify the regulatory status of their chosen manufacturers and ensure that the supplied API meets all necessary quality and compliance requirements for the target markets.

What Is the Current Market Status and Supply Chain Dynamics for Phenprocoumon API?

The market for phenprocoumon API is characterized by a stable, albeit niche, demand driven by its established use as an anticoagulant. Supply chain dynamics are influenced by the consolidated manufacturing base and the generic nature of the drug product.

Key market and supply chain factors:

• Generic Market: Phenprocoumon is an established anticoagulant, and its patent protection has long expired. This means the market is primarily served by generic drug manufacturers, leading to price sensitivity in API sourcing.
• Geographic Concentration: As noted, manufacturing is concentrated in specific regions, primarily Europe and India. This concentration can create supply chain vulnerabilities if geopolitical events, trade disputes, or local regulatory changes impact production or export capabilities.
• Demand Stability: Demand for phenprocoumon is relatively stable, reflecting its clinical use in specific patient populations. However, the introduction of newer oral anticoagulants (NOACs/DOACs) has impacted the overall market share of older vitamin K antagonists like phenprocoumon in some regions, though it retains a significant place in certain therapeutic protocols and geographical markets (e.g., continental Europe).
• Lead Times and Inventory Management: Pharmaceutical companies typically maintain inventory of critical APIs like phenprocoumon to ensure uninterrupted production of finished drug products. Lead times from manufacturers can vary, influenced by production schedules and shipping logistics.
• Supplier Audits: Pharmaceutical companies routinely conduct audits of their API suppliers to ensure ongoing compliance with GMP and quality standards. These audits are a critical component of supplier qualification and risk management.

The supply chain relies on established relationships between API manufacturers and finished dosage form producers, often mediated by distributors or brokers for smaller volume requirements.

What Are the Key Quality Parameters and Specifications for Phenprocoumon API?

Ensuring the quality of phenprocoumon API is paramount for patient safety and therapeutic effectiveness. Quality parameters are defined by pharmacopoeial standards and manufacturer-specific specifications, which are often developed in conjunction with their pharmaceutical clients.

Critical quality attributes and specifications include:

• Appearance: Typically a white to yellowish-white crystalline powder.
• Identification: Confirmatory tests, often using infrared (IR) spectroscopy or high-performance liquid chromatography (HPLC) retention time matching against a reference standard.
• Assay (Purity): The content of phenprocoumon is usually specified as not less than 98.5% and not more than 101.0% on the dried basis, calculated by a validated assay method (e.g., HPLC or titration).
• Related Substances (Impurities): Limits are set for specific known impurities and for total impurities. For example, the Ph. Eur. monograph for phenprocoumon details limits for specific related substances, often in the range of not more than 0.1% for individual impurities and not more than 0.5% for total impurities. Impurities may include synthetic precursors, degradation products, or isomers.
• Loss on Drying: Specifies the maximum amount of volatile matter (primarily water) that the API can contain, typically not more than 0.5%.
• Residue on Ignition (Sulfated Ash): Measures the inorganic content, with limits typically set at not more than 0.1%.
• Heavy Metals: Limits are enforced to ensure the absence of harmful heavy metal contaminants, with values often below 10 ppm or 20 ppm.
• Residual Solvents: Limits for residual solvents used during the manufacturing process are defined according to ICH Q3C guidelines. Common solvents and their acceptable limits must be monitored.
• Particle Size Distribution: While not always a primary pharmacopoeial requirement, particle size can be critical for downstream processing, such as tablet compression or dissolution rates, and may be specified by the drug product manufacturer.

Manufacturers must demonstrate robust quality control systems, including validated analytical methods, to ensure that each batch of phenprocoumon API consistently meets these specifications.

What Are the Comparative Advantages and Disadvantages of Sourcing from Different Regions?

Sourcing phenprocoumon API from different geographical regions presents distinct advantages and disadvantages related to cost, quality, regulatory compliance, and supply chain resilience.

European Manufacturers (e.g., Alp Pharma, Sanico)

• Advantages:
  • High Quality and Regulatory Assurance: European manufacturers generally operate under stringent GMP standards enforced by the EMA and national competent authorities. They often possess CEPs, simplifying regulatory filings for drug product manufacturers in Europe and other regions that recognize CEPs.
  • Established Reputation: Many European API producers have long-standing reputations for reliability and product quality.
  • Proximity: For European drug product manufacturers, sourcing from within the EU can reduce shipping times and costs, and potentially simplify customs procedures.
• Disadvantages:
  • Higher Cost: Production costs in Europe are typically higher than in India, which can translate to a higher API price.
  • Limited Number of Suppliers: The concentration of production can lead to less price competition compared to regions with more numerous producers.

Indian Manufacturers (e.g., Standard Pharmacare Limited)

• Advantages:
  • Cost-Effectiveness: Indian API manufacturers generally offer competitive pricing due to lower labor and operational costs.
  • Large Production Capacity: India is a major global supplier of APIs, with significant manufacturing capacity.
  • Established Regulatory Track Record: Many Indian API manufacturers have successfully undergone inspections by major regulatory agencies like the FDA and EMA and hold DMFs.
• Disadvantages:
  • Potential Quality Variability (Historically): While improving significantly, historical concerns about quality consistency from some Indian manufacturers have existed. Rigorous supplier qualification and auditing are crucial.
  • Supply Chain Complexity: Longer shipping distances and potentially more complex customs procedures can increase lead times and logistical challenges.
  • Intellectual Property Concerns: While less relevant for an off-patent API like phenprocoumon, broader concerns about IP protection can sometimes influence perceptions.

The choice of sourcing region depends on a company's specific priorities regarding cost, quality assurance, regulatory strategy, and supply chain risk tolerance. A diversified sourcing strategy, involving suppliers from different regions, can mitigate risks.

Key Takeaways

The global supply of phenprocoumon API is concentrated among a few manufacturers in Europe and India. Regulatory compliance with GMP, including DMF submissions and pharmacopoeial standards, is critical. The market is dominated by generic competition, leading to price sensitivity. Quality specifications focus on purity, impurity profiles, and physical characteristics, with pharmacopoeial monographs providing the baseline. Sourcing from Europe offers high regulatory assurance but at a higher cost, while India provides cost advantages with the necessity for stringent quality verification.

FAQs

1. What is the typical lead time for sourcing bulk phenprocoumon API from a European manufacturer? Typical lead times can range from 8 to 16 weeks, depending on the manufacturer's current production schedule, order volume, and existing inventory.

2. Are there any specific therapeutic indications where phenprocoumon is still preferred over newer anticoagulants, influencing API demand? Phenprocoumon remains a significant option for patients requiring long-term anticoagulation, particularly in certain indications like mechanical heart valve replacement, and in regions where it has long been established as a standard of care. This localized or specialized demand contributes to consistent, albeit not rapidly growing, API requirements.

3. What is the role of a Certificate of Suitability to the monographs of the European Pharmacopoeia (CEP) in sourcing phenprocoumon API? A CEP simplifies the regulatory submission process for drug product manufacturers seeking marketing authorization in Europe and other regions that accept CEPs. It confirms that the API complies with the European Pharmacopoeia monograph, pre-validating a significant aspect of quality.

4. How can a pharmaceutical company mitigate the risk of supply chain disruption from a single phenprocoumon API manufacturer? Mitigation strategies include qualifying and maintaining relationships with at least two API suppliers from different geographical regions, building safety stock inventory, and developing robust business continuity plans.

5. What are the primary analytical methods used for assay and impurity testing of phenprocoumon API? High-performance liquid chromatography (HPLC) is the predominant method for both assay (quantification of the active ingredient) and related substances (impurity profiling). Titration may also be used for assay in some pharmacopoeial methods.

Citations

[1] European Directorate for the Quality of Medicines & HealthCare. (n.d.). Certificate of Suitability to the monographs of the European Pharmacopoeia (CEP). Retrieved from https://www.edqm.eu/en/certificate-suitability-monographs-european-pharmacopoeia-cep

[2] U.S. Food and Drug Administration. (n.d.). Drug Master Files. Retrieved from https://www.fda.gov/drugs/guidance-compliance-regulatory-information/drug-master-files

[3] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2015). ICH Harmonised Tripartite Guideline: Impurities: Guideline for Residual Solvents Q3C(R6).